Primaquine dispersible

Product development

-

Patient confirmatory

Fosun Pharma

Transmission reduction

Paediatric formulation

Bioequivalence

Prevention of relapse for P. vivax (TPP-1)

Product vision	Product targeting prevention of relapse for P. vivax Product for transmission reduction
Dosing	2.5 mg and 5 mg tablets, 14-day course in all transmission settings to prevent relapse, treat P. vivax or P. ovale malaria in children and adults A single dose of 0.25 mg/kg primaquine with ACT to patients with P. falciparum malaria (except pregnant women, infants aged <6 months and women breastfeeding infants aged < 6 months) to reduce the transmissibility of treated P. falciparum infections in low-transmission settings
Efficacy	WHO guidelines recommend primaquine to prevent relapse, treat P. vivax or P. ovale malaria in children and adults (except populations mentioned above), unless they are known not to be G6PD deficient.
Key features	Would be first child friendly dispersible formulation
Challenges	Limited use in low-transmission settings
Status	Prototype developed and tech transfer undertaken Bioequivalence study protocol WHO Ethics Review Committee (ECR) approved Scaling up the formulation and manufacturing pilot-scale batches for bioequivalence study
Next milestone	Bioequivalence study start in 2023
Project Director	Pierre Hugo